Foundation Fighting Blindness

Foundation Fighting Blindness to honor Doug Zarkin of Pearle Vision and Avi Kaner of Morton Williams Supermarket at 2023 Gala Night for Sight

Retrieved on: 
星期四, 三月 2, 2023
Retina, Janssen Pharmaceuticals, Chelsea Piers, Research, Next Generation, Lighthouse, Hope, Foundation Fighting Blindness, Supermarket, Visual impairment, Johnson & Johnson, France 4 Visionary Award, Pearle Vision, Pharmaceutical industry

COLUMBIA, Md., March 2, 2023 /PRNewswire/ -- The Foundation Fighting Blindness, the world's leading organization committed to finding treatments and cures for blinding retinal diseases, presents its prestigious Visionary Award to Doug Zarkin, Vice President and Chief Marketing Officer of Pearle Vision and Avi Kaner, Co-Owner of Morton Williams Supermarkets through its annual gala, Night for Sight. Taking place on Thursday, May 11 at 6 p.m. ET at The Lighthouse at Chelsea Piers in Manhattan, Night for Sight will celebrate beacons of the fashion, finance, and food industries.

Key Points: 
  • COLUMBIA, Md., March 2, 2023 /PRNewswire/ -- The Foundation Fighting Blindness , the world's leading organization committed to finding treatments and cures for blinding retinal diseases, presents its prestigious Visionary Award to Doug Zarkin, Vice President and Chief Marketing Officer of Pearle Vision and Avi Kaner, Co-Owner of Morton Williams Supermarkets through its annual gala, Night for Sight.
  • ET at The Lighthouse at Chelsea Piers in Manhattan, Night for Sight will celebrate beacons of the fashion, finance, and food industries.
  • Mr. Zarkin represents growth and compassion in the vision community and the Foundation is honored to recognize him at its annual gala in May.
  • "The Foundation Fighting Blindness is excited to be partnering with Doug Zarkin and Avi Kaner through Night for Sight," said Peter Ginsberg, chief operating officer of the Foundation Fighting Blindness.

Foundation Fighting Blindness to Host PRPH2 and Associated Retinal Diseases Workshop

Retrieved on: 
星期三, 一月 25, 2023
Opus, MD, Foundation Fighting Blindness, University, Laboratory, School, MBA, University of Houston, Occult macular dystrophy, Biomedical engineering, MA, UCSD, Retina, Partnership, University of California, San Diego, University of California, Duke University, Public health, School of Public Health, Columbia University, Research, UC San Diego Health, DO, Eye, PRPH2, Visual impairment, Pathology, MBBS, Doctor of Philosophy, Cell biology, Pharmaceutical industry, Management, Ophthalmology

COLUMBIA, Md., Jan. 25, 2023 /PRNewswire/ -- The Foundation Fighting Blindness, the world's leading organization committed to finding treatments and cures for blinding retinal diseases, in partnership with the Nixon Visions Foundation and the Shiley Eye Institute, at the University of California, San Diego, will host the free in-person PRPH2 and Associated Retinal Diseases Workshop on March 29–31, 2023, at the Hilton La Jolla Torrey Pines in San Diego, CA. Registration information can be found at www.FightingBlindness.org/PRPH2Workshop.

Key Points: 
  • COLUMBIA, Md., Jan. 25, 2023 /PRNewswire/ -- The Foundation Fighting Blindness , the world's leading organization committed to finding treatments and cures for blinding retinal diseases, in partnership with the Nixon Visions Foundation and the Shiley Eye Institute, at the University of California, San Diego, will host the free in-person PRPH2 and Associated Retinal Diseases Workshop on March 29–31, 2023, at the Hilton La Jolla Torrey Pines in San Diego, CA.
  • The PRPH2 and Associated Retinal Diseases Workshop is designed to bring together leading experts from academia and industry, to discuss openly, and in detail, what is known about PRPH2 disease pathology, disease models, clinical characteristics, and therapeutic approaches.
  • Claire M. Gelfman, PhD, chief scientific officer, Foundation Fighting Blindness, along with Radha Ayyagari, PhD, Shiley Eye Institute, University of California, San Diego (UCSD), and Shyamanga Borooah, MD, PhD, Shiley Eye Institute, University of California, San Diego (UCSD), will serve as workshop co-chairs.
  • To register for the PRPH2 and Associated Retinal Diseases Workshop and get the latest updates on the event, visit www.FightingBlindness.org/PRPH2Workshop .

Opus Genetics Receives FDA Clearance of IND Application for OPGx-001, a Gene Therapy Candidate Intended for the Treatment of Rare Inherited Retinal Disease LCA5

Retrieved on: 
星期四, 十二月 1, 2022
Triangle Park (Quezon City), Severe cognitive impairment, Science, PARK, Food, Retina, LCA5, IND, Safety, Genetics, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, IPSC, Disease, Leber congenital amaurosis, Foundation Fighting Blindness, Retinal degeneration, LCA, AAV, RESEARCH, FDA, Pharmaceutical industry, Opus

RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first, clinical-stage gene therapy company developing treatments for inherited retinal diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1/2, first-in-human clinical trial of OPGx-001 in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5). OPGx-001 is an adeno-associated virus 8 (AAV8) vector to precisely deliver a functional LCA5 gene to retinal photoreceptors. Currently, there are no approved treatments for individuals with LCA5-related vision loss.

Key Points: 
  • OPGx-001 is an adeno-associated virus 8 (AAV8) vector to precisely deliver a functional LCA5 gene to retinal photoreceptors.
  • This FDA clearance of our IND application for OPGx-001 for LCA5 marks a significant milestone for Opus, as our first program to enter the clinic, said Ben Yerxa, Ph.D., Chief Executive Officer of Opus.
  • OPGx-001 utilizes an adeno-associated virus 8 (AAV8) vector to precisely deliver a functional LCA5 gene to photoreceptors in the retina.
  • Opus Genetics is a clinical-stage gene therapy company for inherited retinal diseases with a unique model and purpose.

Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Russell Kelley

Retrieved on: 
星期二, 十一月 8, 2022
Opus, GLOBE, RD, Duke University, Investment, Eye, Burroughs Wellcome Fund, Retina, Foundation, Cystinosis, Retinal degeneration, Retinitis pigmentosa, Foundation Fighting Blindness, Visual impairment, Science, Gaps, MBA, Cataract, CEO, Oxidative stress, Pharmaceutical industry

FORT WORTH, Texas, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts, and other ocular diseases caused by oxidative stress, today announced the appointment of Russell Kelley, Ph.D., MBA, to its board of directors.

Key Points: 
  • FORT WORTH, Texas, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts, and other ocular diseases caused by oxidative stress, today announced the appointment of Russell Kelley, Ph.D., MBA, to its board of directors.
  • Dr. Kelley currently serves as managing director of the Retinal Degeneration (RD) Fund, the venture arm of Foundation Fighting Blindness and a significant investor of Nacuity.
  • Dr. Kelley is a pharmacologist who brings a wealth of experience advancing life science technologies to Nacuitys board.
  • Dr. Kelley helped launch the RD Fund and has been instrumental in building a portfolio of novel technologies including genetic medicines.

Foundation Launching its Largest Natural History Study to Date for 1,500 People with Inherited Retinal Diseases Caused by Rare Mutated Genes

Retrieved on: 
星期四, 十一月 10, 2022
IRDS, RPE65, Retina, Macular degeneration, Research, Gene, Population, Ophthalmology, Therapy, Nanoparticle, USH2A, Severe cognitive impairment, Company, CEP290, Genetics, University of Pittsburgh School of Medicine, Foundation Fighting Blindness, Wilfrid Sellars, USH1B, Environment, MYO7A, Doctor of Pharmacy, Triangle Park (Quezon City), CNGA3, AAV, Science, Patient, CEO, RHO, CNGB3, MD, RPGR, Doctor of Philosophy, Research Triangle, Foundation, HIV disease progression rates, Retinitis pigmentosa, CHM, Biotechnology, Retinal degeneration, Leber congenital amaurosis, PROM1, IRD, Technology, RDH12, Usher syndrome, PCDH15, University, Visual impairment, Atsena Otie Key, MBA, LCA, Natural history, Pharmaceutical industry, Medical device, Vaccine, Antibiotics, Opus, GUCY2D

COLUMBIA, Md., Nov. 10, 2022 /PRNewswire/ -- The Foundation Fighting Blindness, the world's leading organization committed to finding treatments and cures for blinding retinal diseases, is committing at least $8.6 million for its Uni-Rare Study, a new natural history study for approximately 1,500 people with one of more than 300 rare genes associated with inherited retinal diseases (IRDs) including: retinitis pigmentosa, Leber congenital amaurosis, Usher syndrome, and a broad range of other conditions.

Key Points: 
  • "A majority of the 300 genes linked to inherited retinal diseases have not been well characterized in the clinic.
  • "We are excited to launch a highly inclusive study to benefit a large segment of the population affected by IRDs, which are so genetically diverse."
  • Established in 1971, the Foundation Fighting Blindness is the world's leading private funding source for retinal degenerative disease research.
  • Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose.

Battling Blindness: Virtual Investor Event on Treatments for Retinitis Pigmentosa to Be Held October 19; Panelists include Kiora Pharmaceuticals, Foundation Fighting Blindness, and Retinal Surgeon Christine Kay, M.D.

Retrieved on: 
星期三, 九月 28, 2022
Retinitis pigmentosa, RP, Foundation Fighting Blindness, Time, IRD, Ophthalmology, Foundation, NASDAQ, Research, CDO, Visual impairment, Telescopic sight, Pharmaceutical industry

Participants will include Christine Kay, M.D., Vitreoretinal surgeon and IRD specialist at Vitreoretinal Associates, Eric Daniels, M.D., CDO of Kiora Pharmaceuticals (NASDAQ: KPRX) and Ben Shaberman, Ph.D., from the Foundation Fighting Blindness.

Key Points: 
  • Participants will include Christine Kay, M.D., Vitreoretinal surgeon and IRD specialist at Vitreoretinal Associates, Eric Daniels, M.D., CDO of Kiora Pharmaceuticals (NASDAQ: KPRX) and Ben Shaberman, Ph.D., from the Foundation Fighting Blindness.
  • The 30 minute event will be held Wednesday, October 19, 2022 at 4:30 PT Eastern Time.
  • Panelists will discuss investigational treatments for RP, ranging from gene and cell therapies to photoresponsive small molecules.
  • Panelists will include a leading retinal surgeon, Kiora Pharmaceuticals and Foundation Fighting Blindness.

RD Fund Participates in a €75 Million Series B for SparingVision

Retrieved on: 
星期四, 九月 15, 2022
RP, Retinitis pigmentosa, Therapy, Foundation Fighting Blindness, Disease, Intellia Therapeutics, Retina, Usher syndrome, Patient, MBA, Visual acuity, Severe cognitive impairment, Doctor of Philosophy, Foundation, Macular degeneration, Research, Genome, IRDS, Color, Visual impairment, Pharmaceutical industry, Antibiotics

RALEIGH, N.C., Sept. 15, 2022 /PRNewswire/ -- Today, the RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness aimed at rapidly driving research toward preventions, treatments, and cures for the entire spectrum of retinal degenerative diseases – announces its participation in a €75 million Series B financing for SparingVision. The round was co-led by Jeito Capital and UPMC Enterprises, with participation from 4BIO Capital, Bpifrance, Ysios Capital, and the RD Fund.

Key Points: 
  • RALEIGH, N.C., Sept. 15, 2022 /PRNewswire/ -- Today, the RD Fund (Retinal Degeneration Fund) the venture arm of the Foundation Fighting Blindness aimed at rapidly driving research toward preventions, treatments, and cures for the entire spectrum of retinal degenerative diseases announces its participation in a 75 million Series B financing for SparingVision .
  • The round was co-led by Jeito Capital and UPMC Enterprises , with participation from 4BIO Capital, Bpifrance , Ysios Capital, and the RD Fund.
  • SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments.
  • "Our investment reflects the long-term funding and investment strategies of the Foundation and the RD Fund to bring forward a pipeline of novel therapeutics, including SparingVision's genetic medicines," said Rusty Kelley, PhD, MBA, managing director, RD Fund and SparingVision board director.

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases

Retrieved on: 
星期三, 九月 14, 2022
Retinitis pigmentosa, RP, Retina, Outline of health sciences, Foundation Fighting Blindness, Twitter, UPMC, Stargardt disease, CRISPR, University of Pittsburgh School of Medicine, Intellia Therapeutics, LinkedIn, Company, Gene, Growth, Therapy, Severe cognitive impairment, Usher syndrome, Patient, Investment, The New England Journal of Medicine, Cell, Nature, Solution, Foundation, Science, NASDAQ, Do Meu Jeito, Macular degeneration, Research, University, Mutation, Genome, IRDS, Visual impairment, NTLA, Pharmaceutical industry, Lancet

SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments.

Key Points: 
  • SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments.
  • Leveraging its unparalleled understanding of retinal diseases, SparingVision has built the worlds most compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for inherited retinal diseases (IRDs).
  • The Company also has a strategic collaboration with Intellia Therapeutics (NASDAQ: NTLA) to develop novel genome editing-based treatments for ocular diseases utilizing CRISPR-Cas9 technology.
  • Inherited retinal diseases are a group of progressive eye conditions that can cause severe vision loss and, in certain cases, lead to total blindness.

Jeito Capital co-leads €75 million Series B financing in SparingVision

Retrieved on: 
星期三, 九月 14, 2022
Professional Services, Health, Genetics, Finance, Pharmaceutical, Optical, Biotechnology, Retinitis pigmentosa, Retina, Foundation Fighting Blindness, Capital, Private equity, Ophthalmology, Intellia Therapeutics, Company, FFB, Therapy, Patient, Investment, CEO, Technology, Severe cognitive impairment, Foundation, NASDAQ, Genomics, Research, AMD, University, IRDS, NTLA, Pharmaceutical industry, Do Meu Jeito

Jeito Capital ("Jeito"), a leading independent Private Equity firm dedicated to biotech and biopharma, announced today that it has co-led a Series B financing round in SparingVision, a privately held French biotech company.

Key Points: 
  • Jeito Capital ("Jeito"), a leading independent Private Equity firm dedicated to biotech and biopharma, announced today that it has co-led a Series B financing round in SparingVision, a privately held French biotech company.
  • In co-leading this Series B financing, Jeito Capital is demonstrating its commitment to invest significant capital in continuity, throughout the different development stages of a promising biotech company, to build market leaders with accelerated patients access globally, especially in Europe and the United States.
  • Our new investment in SparingVision illustrates perfectly Jeito Capital's mission to build market leaders with global reach to bring ground-breaking therapies to patients with high unmet needs.
  • Sabine Dandiguian, Managing Partner of Jeito, said: We are very pleased to support the success of SparingVision's incredible management team.

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases

Retrieved on: 
星期三, 九月 14, 2022
Retinitis pigmentosa, RP, Retina, Outline of health sciences, Foundation Fighting Blindness, Twitter, UPMC, Stargardt disease, CRISPR, University of Pittsburgh School of Medicine, Intellia Therapeutics, LinkedIn, Company, Gene, Growth, Therapy, Severe cognitive impairment, Usher syndrome, Patient, Investment, The New England Journal of Medicine, Cell, Nature, Solution, Foundation, Science, NASDAQ, Do Meu Jeito, Macular degeneration, Research, University, Mutation, Genome, IRDS, Visual impairment, NTLA, Pharmaceutical industry, Lancet

SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments.

Key Points: 
  • SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments.
  • Leveraging its unparalleled understanding of retinal diseases, SparingVision has built the worlds most compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for inherited retinal diseases (IRDs).
  • The Company also has a strategic collaboration with Intellia Therapeutics (NASDAQ: NTLA) to develop novel genome editing-based treatments for ocular diseases utilizing CRISPR-Cas9 technology.
  • Inherited retinal diseases are a group of progressive eye conditions that can cause severe vision loss and, in certain cases, lead to total blindness.